Vaccine in Medical Technology

Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA

... with public health officials in producing a vaccine against the influenza A(H1N1) 2009 virus ," said ... Pasteur. "It is essential that we pursue the vaccine licensure pathway made available to us, while at ... Pasteur's influenza A(H1N1) 2009 monovalent vaccine supplemental application specifies the evaluation ...

NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone

... it has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza ... good-manufacturing practices (cGMP) at its new vaccine manufacturing facility in Rockville, MD. This ... to produce almost all of the world's influenza vaccine supply. In addition, Novavax has produced ...

Society of Gynecologic Oncologists Issues White Paper on HPV Vaccine's Impact on Cervical Cancer Prevention

... cervical cancer screening, strategies to measure vaccine uptake and obstacles surrounding separate ... that if administered prior to first exposure, the vaccine can prevent up to 70 percent of cervical cancers. ... Forum focused on cervical cancer in the HPV vaccine era and was attended by more than 50 ...

Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy

... distant metastatic melanoma were injected with a vaccine that included each patient's own immune cells ... in the laboratory. The patient-specific vaccine is designed to stimulate the patient's immune ... p=.016). Eight patients in the dendritic cell vaccine study experienced remarkable long-term, ...

AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine

... studies of its H1N1 (swine) influenza vaccine and will manufacture clinical trial material by the end of the month. This vaccine has shown good production yields as well as ... after just a single inoculation. "Our vaccine platform provides several potential advantages ...

Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet

... the largest efficacy trial of a cervical cancer vaccine is published today in The Lancet . The study, ... types, 16 and 18. The study also showed that the vaccine provides cross-protection against HPV types 31, ... 18. For the first time the results show that this vaccine was effective against cervical pre-cancers ...

New Review on PROSTVAC(TM) Published by Key Investigators From NCI

... view on PROSTVAC(TM) and the potential use of the vaccine in earlier stages of the disease. We are looking ... information: PROSTVAC(TM) is a therapeutic vaccine moving into late stage clinical development that ... is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts ...

GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting

... conducting Phase 2a clinical trials for an AIDS vaccine in the U.S., excellent safety and immune ... U.S. National Institutes of Health-sponsored HIV vaccine Trials Network (HVTN). Planning is progressing ... our $17 million NIH grant to enhance our vaccine development." Dr. McNally added, "We also ...

CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas

... (Ligand Epitope Antigen Presentation System) vaccine technology with specificity for particular ... herpes simplex virus (HSV) glycoprotein to make a vaccine that induces a defined immune response. Last ... against HSV and HIV. The use of the L.E.A.P.S. vaccine technology may thus open a whole new way of ...

Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech

... was announced on April 21, 2009 at the World vaccine Congress Washington conference. The vaccine Industry Excellence awards recognize the ... of companies and individuals working in the vaccine industry. Sanaria was named Best ...

PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)

... recombinant protective antigen (rPA) anthrax vaccine Valortim(R) - a fully human monoclonal ... RypVax(TM) - a recombinant dual antigen vaccine for plague A third generation rPA anthrax ... an Anthrax Recombinant Protective Antigen (rPA) vaccine for the Strategic National Stockpile, the award ...

Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS

... investigating the effectiveness of Intercell's vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine started today in the U.S. - The study is ... influenza outbreak with only a single dose vaccine application VIENNA and GAITHERSBURG, Md., ...

PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA

... 25 million doses of a next generation rPA anthrax vaccine for the country's civilian biomedical stockpile. ... generation recombinant protective (rPA) anthrax vaccine being developed for administration by ... recombinant protective antigen (rPA) anthrax vaccine Third generation rPA ...

Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine

... the years, I found Dr. Robinson's quest for a vaccine hitting very close to home." "Being involved ... of treatment is only affordable by the wealthy; a vaccine solution which can be accessed by all is a key. ... making the necessary headway needed to make this vaccine a reality for the good of humanity." About ...

Novel Vaccine Approach Offers Hope in Fight Against HIV

... approach that bypasses the usual path followed by vaccine developers. By using gene transfer technology ... that was the target of all previous HIV and SIV vaccine candidates," said study leader Philip R. Johnson, ... this animal study might be translated into an HIV vaccine for humans. If the technique leads to an ...

Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial

... placebo-controlled study is evaluating a VLP vaccine against the H3N2, H1N1, and B influenza strains ... of safety and immunogenicity of a broad range of vaccine doses against a new set of influenza strains. As ... first Phase II study evaluated a trivalent VLP vaccine against the seasonal influenza strains that ...

AlphaVax Announces Promising Results in Melanoma Studies

... Immunotherapeutic intervention with a novel vaccine vector such as ours may prove beneficial as a ... A phase I/II clinical trial for a CEA tumor vaccine is currently ongoing at Duke University and a ... immunotherapy programs, AlphaVax is developing vaccine products for herpes simplex virus, influenza, ...

PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program

... E.T., to review the status of its rPA anthrax vaccine program. The dial-in number within the ... recombinant protective antigen (rPA) anthrax vaccine Third generation rPA anthrax vaccine Valortim(R) - a fully human monoclonal ...

Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference

... /PRNewswire/ -- Global progress toward a malaria vaccine is among the key topics to be presented at the 12th Annual Conference on vaccine Research (ACVR), sponsored by the National ... a swath of Africa; use of an adjuvant to expand vaccine coverage in the event of a bird-flu epidemic; and ...

Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin

... in humans watershed moment for unique malaria vaccine approach ROCKVILLE, Md., April 23 ... Sanaria Inc., with support from the PATH Malaria vaccine Initiative (MVI), has initiated a Phase 1 ... in adult volunteers -- of its unique malaria vaccine candidate. Unlike other ...

Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine

... obtain safety and immunogenicity data of this new vaccine candidate - Initial results expected in Q4 ... of Intercell's Streptococcus pneumoniae vaccine supported by PATH VIENNA, April 7 ... that a Phase I clinical trial with the company's vaccine candidate IC47 to prevent disease caused by the ...

Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology

... recombinant protective antigen (rPA) anthrax vaccine Valortim(R) - a fully human monoclonal ... RypVax(TM) - a recombinant dual antigen vaccine for plague A third generation rPA anthrax ... an Anthrax Recombinant Protective Antigen (rPA) vaccine for the Strategic National Stockpile, the award ...

Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development

... 13 /PRNewswire-FirstCall/ -- Nobilon, the human vaccine business unit of Schering-Plough Corporation ... a new intranasal Live Attenuated Influenza vaccine (LAIV) for annual seasonal use. The candidate vaccine is composed of the three attenuated Influenza ...

Children's Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia

... a Gates Foundation grant) showing that influenza vaccine not only prevents pregnant women from getting the ... trial in an urban setting, that the influenza vaccine protects both mothers and their children," says ... flu vaccination in low-resource areas." Flu vaccine is already recommended and used in pregnant women ...

BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine

... 70% of evaluated patients. Clinically, the vaccine was well tolerated with no ... after a 6 month period. Also, in the group where vaccine was combined with chemotherapy, one complete ... bring this new and improved version of the HER2 vaccine further through clinical development." ...

GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA

... first injections in its Phase 2a Human Clinical vaccine Trial for its candidate HIV/AIDS vaccine. The ... HVTN 205, is being conducted by the HIV vaccine Trials Network (HVTN). The HVTN, funded ... trial will include a total of 225 volunteers (150 vaccine recipients and 75 placebo recipients) and take ...

Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate

... pandemic influenza virus-like particle (VLP) vaccine candidate that provided protection against ... immunized with this broadly protective H5N1 VLP vaccine candidate. The H5N1 VLP contains three proteins, ... In this study, two injections of the VLP vaccine candidate resulted in 100% survival of mice that ...

Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study

... today that its investigational tetravalent dengue vaccine is entering into a pediatric clinical study in Thailand to assess the efficacy of the vaccine in protecting children against dengue, the most ... malaria. Sanofi Pasteur's tetravalent dengue vaccine candidate is the first to reach this stage of ...

Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference

... VLP vaccine - Coupled with Innovative Manufacturing - Has ... its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain ... have been fatal. (1) In this study, the vaccine demonstrated strong HAI antibody titers against ...

Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile

... vaccine. While the target indication for the vaccine is primary prevention of C. difficile infection ... aims at providing early proof of concept of the vaccine approach. "Treatment of C. difficile ... of the trial. Sanofi Pasteur's candidate vaccine uses a toxoid-based approach, which has been used ...

Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers' Diarrhea Vaccine Study

... III clinical trial of a Travelers' Diarrhea (TD) vaccine system. The TD vaccine is in the form of a skin patch -- a novel method for delivering a vaccine that is especially compelling because it is ...

Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer

... Cross will become the only seasonal influenza vaccine manufacturer in South Korea and also is developing avian influenza vaccine. In its vaccine business, Green Cross has successfully developed ... B (Hepavax), the first Epidemic Hemorrhagic Fever vaccine and the world's second chicken pox vaccine. Green ...

USD 12.5 m Funding for the Development of Intercell's Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)

... Intercell is developing a Pandemic Influenza vaccine Patch System that includes an immunostimulant ... conjunction with an injected Pandemic Influenza vaccine (manufactured by Solvay Biologicals, B.V., ... and dose of an injected H5N1 influenza vaccine and ...

Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate

... Favorable immunogenicity results for seasonal vaccine program follows positive results from its pandemic influenza vaccine Phase IIa trial in July 2008; plans to initiate a study of the seasonal vaccine in the elderly in 2009 ROCKVILLE, Md., ...

AFFiRiS Begins Development of a Parkinson's Vaccine

... development of its first Parkinson's vaccine PD01. The vaccine will be investigated for ... could start in 2010/11. The Parkinson's vaccine specifically targets the alpha-synuclein ... working on animal models. The Parkinson's vaccine from AFFiRiS has been developed to ...

Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans

... data from the company's RapidResponse(TM) DNA vaccine manufacturing program, this week at the DNA ... December 9-11). H5N1 Pandemic Influenza vaccine Phase 1 Trial Update New data presented at ... H5N1 pandemic influenza DNA vaccine induced T-cell responses against the H5 antigen ...

Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization

... such as type 1 diabetes. In other individuals vaccine induced inflammation is countered by release of ... 2 diabetes. Classen has previously demonstrated vaccine induced type 1 diabetes has a strong ... diabetes have a much greater risk of developing vaccine induced type 1 diabetes. In a previous ...

SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial

... results from a Phase I clinical trial of a DNA vaccine for severe acute respiratory syndrome (SARS), ... 25 issue of Vaccine(1), demonstrated that the vaccine was well-tolerated, and induced neutralizing ... SARS coronavirus genetic sequence from which the vaccine was derived, and was the first SARS vaccine human ...

Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa

... that the world's most clinically advanced malaria vaccine candidate provides both infants and young ... GSK ) Biologicals' RTS,S/AS vaccine candidate across Africa(1),(2). In infants, data show for the first time that the vaccine candidate can be administered as part of existing ...

Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate

... Novavax's first vaccine candidate for the prevention of RSV ... the results of a preclinical study of a vaccine candidate for the prevention of respiratory syncytial virus ("RSV") at the 2nd vaccine Congress in Boston, MA on December 9, 2008. This ...